Investigation on Efficacy and Safety of Apixaban in Japanese Elderly Patients: Investigator-Initiated Multicenter Prospective Cohort Study
- Conditions
- non-valvular atrial fibrillation (NVAF)
- Registration Number
- JPRN-UMIN000017895
- Lead Sponsor
- The Cardiovascular Institute Academic Organization (CVI ARO)
- Brief Summary
Event rates (/100 person-years) in standard and reduced dose groups were 1.67 and 1.56, respectively, for stroke or systemic embolism, 1.42 and 2.25 for bleeding requiring hospitalization, 1.41 and 4.46 for total death, and 0.41 and 1.36 for cardiovascular death.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3031
Not provided
(1) Apixaban hypersensitivity (2) Clinically significant bleeding (3) River dysfunction with clotting disorder (4) Renal dysfunction (creatinine clearance <15 mL/min) (5) Mitral stenosis and prosthetic valve (6) Inadequate dosage of apixaban at registration (2.5 mg twice a day for those without indications for reducing dose, or 5 mg twice a day for those with them) (7) Patients who did not give written informed consents for this study (8) Venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism) (9) Patients who are judged by the researchers as inadequate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method